Semaglutide vs. Tirzepatide: Which GLP-1 Medication Is Right for You?
Semaglutide: 15–17% avg weight loss, oral options available, from $99/mo compounded. Tirzepatide: 20–22% avg, dual-action, from $133/mo. Here's how to choose.
These are the two medications driving the GLP-1 revolution — and the question patients ask most often is simple: which one should I take? The answer depends on your weight loss goals, your budget, your tolerance for side effects, and how your body responds. Here's the data-backed comparison.
How They Work: One Hormone vs. Two
Semaglutide (brand names: Wegovy, Ozempic) targets the GLP-1 receptor. It mimics the GLP-1 hormone your body naturally produces after eating, which regulates appetite, slows gastric emptying, and improves insulin sensitivity.
Tirzepatide (brand names: Zepbound, Mounjaro) targets both the GLP-1 and GIP receptors — a "dual agonist." GIP (glucose-dependent insulinotropic polypeptide) adds an additional layer of appetite regulation and metabolic signaling that GLP-1 alone doesn't provide.
Think of it this way: semaglutide pulls one lever. Tirzepatide pulls two.
Weight Loss: Head-to-Head Data
In the STEP clinical trials, patients on semaglutide 2.4mg lost an average of 15–17% of their body weight over 68 weeks. In the SURMOUNT trials, patients on tirzepatide at the highest dose (15mg) lost an average of 20–22% — with some participants losing over 25%.
Tirzepatide consistently outperforms semaglutide on average weight loss. However, individual response varies significantly — some patients respond better to semaglutide than tirzepatide, and vice versa. The averages don't predict your personal result.
Side Effects Compared
Both medications share similar GI side effects — nausea, vomiting, diarrhea, constipation — because they both act on the GLP-1 pathway. The rates are roughly comparable, though some studies suggest tirzepatide may have slightly lower rates of nausea at equivalent efficacy levels.
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Avg Weight Loss | 15–17% | 20–22% |
| Mechanism | GLP-1 only | GLP-1 + GIP dual |
| Injection Frequency | Weekly | Weekly |
| Oral Option | Yes (Wegovy pill, Rybelsus) | No (injectable only) |
| Compounded Available | From $99/mo | From $133/mo |
| Brand-Name Cost | $349–499/mo (self-pay) | $349–599/mo (self-pay) |
| Cardiovascular Data | SELECT trial: 20% CV risk reduction | SURPASS-CVOT: ongoing |
Which One Should You Start With?
- Maximum weight loss is the priority → Tirzepatide has higher averages
- Budget is the deciding factor → Compounded semaglutide is cheaper ($99 vs $133/mo)
- Want an oral option → Only semaglutide has FDA-approved pills
- Cardiovascular risk is a concern → Semaglutide has proven CV benefit data (SELECT trial)
- Haven't tried either → Most providers start with semaglutide due to longer track record and lower cost, then switch to tirzepatide if response is insufficient
Many providers offer both medications, allowing you to switch if your first choice doesn't deliver the results or tolerability you need: